Nasdaq
$1.27▼ 0.39%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $168.9MShares out 1.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 9.23Pre-market26.09.23 21:006-KKey event#●●●#●●●#●●●
ProQR Therapeutics N.V.Bullish
ProQR Therapeutics has appointed Chris Hart as Chief Data and AI Officer and Thomas Wolf as a strategic AI advisor to strengthen its AI-driven drug discovery capabilities. The company plans to integrate AI into its Axiomer RNA editing platform to accelerate development, with up to 5 clinical data readouts expected across 4 programs over the next 12 months.…more
$1.27-0.39%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.9Pre-market26.09.09 21:006-KKey event
ProQR Therapeutics N.V.
ProQR Therapeutics has initiated the first participant dosing in a Phase 1 clinical trial of AX-0811, an investigational RNA editing therapy for cholestatic liver diseases. The company will host a virtual investor and analyst educational event on September 30, 2026, to discuss clinical development strategies and review AX-0810 data.…more
$1.27-0.39%vs prev closeView filingShare - 8.13Pre-market26.08.13 20:006-KKey event
ProQR Therapeutics N.V.
ProQR Therapeutics reported Q2 2026 revenue of €8.76 million and a net loss of €8.73 million (€0.08 per share). The company secured $59.2 million in financing in June, extending its cash runway through mid-2028, and achieved the first clinical validation of its Axiomer RNA editing platform with positive Phase 1 data for AX-0810.…more
$1.27-0.39%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.23Pre-market26.09.23 21:00#●●●#●●●#●●●
ProQR Appoints AI Leadership to Accelerate Drug Discovery
ProQR Therapeutics has appointed a new Chief Data and AI Officer and a strategic AI advisor to enhance its drug discovery platform. While this move aims to scale AI integration, it remains a strategic management change without immediate financial impact.…more
$1.27-0.39%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.9Pre-market26.09.09 21:00
●●●●●●●● ●●●●● ●●●●●●
ProQR Therapeutics has initiated the first participant dosing in its Phase 1 clinical trial for AX-0811, an RNA editing candidate for cholestatic liver diseases. The company will host a virtual investor event on September 30, 2026, to discuss the development strategy for this program.…more
$1.27-0.39%vs prev close - 8.13Pre-market26.08.13 20:00
●●●●●●●● ●●●●● ●●●●●●
ProQR has achieved the first clinical validation of its Axiomer RNA editing platform, supporting the advancement of its key therapeutic pipeline. The company also raised approximately $59.2 million in financing, extending its cash runway through mid-2028.…more
$1.27-0.39%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report